Q3-osavuosiraportti
7 päivää sitten‧33 min
Tarjoustasot
Määrä
Osto
140
Myynti
Määrä
378
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
7,75VWAP
Alin
7,5VaihtoMäärä
3,8 667 357
VWAP
Ylin
7,75Alin
7,5VaihtoMäärä
3,8 667 357
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q2-osavuosiraportti | 7.8. | |
| 2025 Yhtiökokous | 4.6. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 6.3. |
Datan lähde: Morningstar, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·7.11.Here's what ChatGPT says: Here is a review of why the stock of Xeris Biopharma Holdings, Inc. (ticker XERS) fell by around 20 % yesterday, whether the drop seems rational, what was reported, and what the company and analysts say going forward. ⸻ Why did the stock fall so much? Although the Q3 2025 figures were strong in many ways, the market reacted negatively. The main reasons: • Xeris reported revenue of approx. US$ 74.4 mill., up ~37 % from the same period last year.  • EPS was taken as “break-even” (US$0.00) against an estimate of US$0.01.  • Although revenue grew well, some product segments were weaker than expected: for example, the analysis reported that “Keveyis” had revenue of ~US$ 11.94 mill vs expectation ~US$ 36.23 mill, according to a source.  • The market probably had higher expectations for both margins, profitability and/or future prospects – meaning: even with good growth, it felt like “not quite enough” or “high expectation that was not met”. • Even though the company adjusted its full-year guidance to ~US$ 285-290 mill for 2025.  • The combination of “strong growth” but also “some disappointment” + high expectation = typical for drops like this. Thus, the drop seems understandable and partly rational, given that market investors react not only to something being good, but to it being better than what they expected – and here it was a bit “not fully” on certain key parameters. ⸻ Were the figures historically bad? Or was much better expected? • It was not “historically bad” – on the contrary: growth is good. The Recorlev product increased by ~109 % year-over-year to ~US$ 37 mill.  • But expectations were higher in certain areas (e.g., certain product segments, margins, EPS) – and it was a bit “under” there. For example: “Keveyis” vs estimate.  • In summary: the figures are strong, but market expectations were perhaps even stronger – and when you have a stock that has risen a lot (the stock had recently been at 52-week highs) then the demands become higher.  ⸻ What does the company itself say? • The company reports that they have “strong top-line growth” and are driving “solid demand” across all three commercial products.  • They point out that the product portfolio (especially Recorlev) has good momentum – Recorlev rose ~109 % year-over-year to ~US$ 37 mill.  • They adjusted the full-year guidance, which is positive initially.  • They also mentioned increased investments in pipeline and technology platform development which drives costs and uncertainty.  • In short: management is optimistic but acknowledges that they must continue to deliver – and that risk still exists. ⸻ What do analysts and the market say about the future? • The consensus rating for the stock is “Moderate Buy” according to MarketBeat, with a price target around US$ 8.92.  • Other analyses are a bit more conservative: Zacks gives the stock a rank #4 (“Sell”) right after the report, with the justification that EPS estimates are disappointing.  • “Simply Wall St” says that while growth is good, much of the future valuation rests on the success of pipeline assets and that the company is still dependent on a limited product set – the risk is still present.  • There are also analyses that believe today's price may already reflect much of the growth (“may be fairly priced”).  ⸻ Is it likely that the drop will continue today? It's never possible to say with certainty, but some considerations: • When a stock falls ~20 % in one day, it can be an “emotion-driven” move (investors locking in gains, readjusting expectations). • If no new negative news emerges, one can expect the drop to subside / stabilize – but the risk of further decline is present if: • Negative signals emerge from the pipeline or competition • The market gets the impression that management is not delivering going forward • Given that the figures were not catastrophic but a bit “disappointing” relative to expectations, today's price development will also depend on what the next quarter/year shows, and how the market interprets indications from the company. ⸻ Brief summary • Xeris delivered good growth, but some expectations were not fully met – especially profitability and certain product segments. • The market likely reacted to a “high bar” and some disappointment, even though the results are solid. • The company is optimistic and has adjusted guidance – but the risk is still open (limited product portfolio, pipeline uncertainty). • Analysts are divided – some see good growth opportunities, others believe the risk is now greater and that the stock may be highly priced. • If the drop continues today: possible, but dependent on sentiment and any new information – stabilization is as likely as further decline.
·6.11.First stock I ever bought. I'm 16 years old, my friend said I should… really bought 24 before it went down 20%. Getting completely traumatized here.
·7.11.Just take it easy. I bought it back in '21 and a couple of months after that it was at -50%. I've held it and until yesterday it was at +165%, so give it time.
·6.11.Panic selling… I'm holding steady. Record quarter. I guess this is just an overreaction.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
7 päivää sitten‧33 min
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7.11.Here's what ChatGPT says: Here is a review of why the stock of Xeris Biopharma Holdings, Inc. (ticker XERS) fell by around 20 % yesterday, whether the drop seems rational, what was reported, and what the company and analysts say going forward. ⸻ Why did the stock fall so much? Although the Q3 2025 figures were strong in many ways, the market reacted negatively. The main reasons: • Xeris reported revenue of approx. US$ 74.4 mill., up ~37 % from the same period last year.  • EPS was taken as “break-even” (US$0.00) against an estimate of US$0.01.  • Although revenue grew well, some product segments were weaker than expected: for example, the analysis reported that “Keveyis” had revenue of ~US$ 11.94 mill vs expectation ~US$ 36.23 mill, according to a source.  • The market probably had higher expectations for both margins, profitability and/or future prospects – meaning: even with good growth, it felt like “not quite enough” or “high expectation that was not met”. • Even though the company adjusted its full-year guidance to ~US$ 285-290 mill for 2025.  • The combination of “strong growth” but also “some disappointment” + high expectation = typical for drops like this. Thus, the drop seems understandable and partly rational, given that market investors react not only to something being good, but to it being better than what they expected – and here it was a bit “not fully” on certain key parameters. ⸻ Were the figures historically bad? Or was much better expected? • It was not “historically bad” – on the contrary: growth is good. The Recorlev product increased by ~109 % year-over-year to ~US$ 37 mill.  • But expectations were higher in certain areas (e.g., certain product segments, margins, EPS) – and it was a bit “under” there. For example: “Keveyis” vs estimate.  • In summary: the figures are strong, but market expectations were perhaps even stronger – and when you have a stock that has risen a lot (the stock had recently been at 52-week highs) then the demands become higher.  ⸻ What does the company itself say? • The company reports that they have “strong top-line growth” and are driving “solid demand” across all three commercial products.  • They point out that the product portfolio (especially Recorlev) has good momentum – Recorlev rose ~109 % year-over-year to ~US$ 37 mill.  • They adjusted the full-year guidance, which is positive initially.  • They also mentioned increased investments in pipeline and technology platform development which drives costs and uncertainty.  • In short: management is optimistic but acknowledges that they must continue to deliver – and that risk still exists. ⸻ What do analysts and the market say about the future? • The consensus rating for the stock is “Moderate Buy” according to MarketBeat, with a price target around US$ 8.92.  • Other analyses are a bit more conservative: Zacks gives the stock a rank #4 (“Sell”) right after the report, with the justification that EPS estimates are disappointing.  • “Simply Wall St” says that while growth is good, much of the future valuation rests on the success of pipeline assets and that the company is still dependent on a limited product set – the risk is still present.  • There are also analyses that believe today's price may already reflect much of the growth (“may be fairly priced”).  ⸻ Is it likely that the drop will continue today? It's never possible to say with certainty, but some considerations: • When a stock falls ~20 % in one day, it can be an “emotion-driven” move (investors locking in gains, readjusting expectations). • If no new negative news emerges, one can expect the drop to subside / stabilize – but the risk of further decline is present if: • Negative signals emerge from the pipeline or competition • The market gets the impression that management is not delivering going forward • Given that the figures were not catastrophic but a bit “disappointing” relative to expectations, today's price development will also depend on what the next quarter/year shows, and how the market interprets indications from the company. ⸻ Brief summary • Xeris delivered good growth, but some expectations were not fully met – especially profitability and certain product segments. • The market likely reacted to a “high bar” and some disappointment, even though the results are solid. • The company is optimistic and has adjusted guidance – but the risk is still open (limited product portfolio, pipeline uncertainty). • Analysts are divided – some see good growth opportunities, others believe the risk is now greater and that the stock may be highly priced. • If the drop continues today: possible, but dependent on sentiment and any new information – stabilization is as likely as further decline.
- ·6.11.First stock I ever bought. I'm 16 years old, my friend said I should… really bought 24 before it went down 20%. Getting completely traumatized here.·7.11.Just take it easy. I bought it back in '21 and a couple of months after that it was at -50%. I've held it and until yesterday it was at +165%, so give it time.
- ·6.11.Panic selling… I'm holding steady. Record quarter. I guess this is just an overreaction.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
140
Myynti
Määrä
378
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
7,75VWAP
Alin
7,5VaihtoMäärä
3,8 667 357
VWAP
Ylin
7,75Alin
7,5VaihtoMäärä
3,8 667 357
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q2-osavuosiraportti | 7.8. | |
| 2025 Yhtiökokous | 4.6. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 6.3. |
Datan lähde: Morningstar, Quartr
Q3-osavuosiraportti
7 päivää sitten‧33 min
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q2-osavuosiraportti | 7.8. | |
| 2025 Yhtiökokous | 4.6. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 6.3. |
Datan lähde: Morningstar, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7.11.Here's what ChatGPT says: Here is a review of why the stock of Xeris Biopharma Holdings, Inc. (ticker XERS) fell by around 20 % yesterday, whether the drop seems rational, what was reported, and what the company and analysts say going forward. ⸻ Why did the stock fall so much? Although the Q3 2025 figures were strong in many ways, the market reacted negatively. The main reasons: • Xeris reported revenue of approx. US$ 74.4 mill., up ~37 % from the same period last year.  • EPS was taken as “break-even” (US$0.00) against an estimate of US$0.01.  • Although revenue grew well, some product segments were weaker than expected: for example, the analysis reported that “Keveyis” had revenue of ~US$ 11.94 mill vs expectation ~US$ 36.23 mill, according to a source.  • The market probably had higher expectations for both margins, profitability and/or future prospects – meaning: even with good growth, it felt like “not quite enough” or “high expectation that was not met”. • Even though the company adjusted its full-year guidance to ~US$ 285-290 mill for 2025.  • The combination of “strong growth” but also “some disappointment” + high expectation = typical for drops like this. Thus, the drop seems understandable and partly rational, given that market investors react not only to something being good, but to it being better than what they expected – and here it was a bit “not fully” on certain key parameters. ⸻ Were the figures historically bad? Or was much better expected? • It was not “historically bad” – on the contrary: growth is good. The Recorlev product increased by ~109 % year-over-year to ~US$ 37 mill.  • But expectations were higher in certain areas (e.g., certain product segments, margins, EPS) – and it was a bit “under” there. For example: “Keveyis” vs estimate.  • In summary: the figures are strong, but market expectations were perhaps even stronger – and when you have a stock that has risen a lot (the stock had recently been at 52-week highs) then the demands become higher.  ⸻ What does the company itself say? • The company reports that they have “strong top-line growth” and are driving “solid demand” across all three commercial products.  • They point out that the product portfolio (especially Recorlev) has good momentum – Recorlev rose ~109 % year-over-year to ~US$ 37 mill.  • They adjusted the full-year guidance, which is positive initially.  • They also mentioned increased investments in pipeline and technology platform development which drives costs and uncertainty.  • In short: management is optimistic but acknowledges that they must continue to deliver – and that risk still exists. ⸻ What do analysts and the market say about the future? • The consensus rating for the stock is “Moderate Buy” according to MarketBeat, with a price target around US$ 8.92.  • Other analyses are a bit more conservative: Zacks gives the stock a rank #4 (“Sell”) right after the report, with the justification that EPS estimates are disappointing.  • “Simply Wall St” says that while growth is good, much of the future valuation rests on the success of pipeline assets and that the company is still dependent on a limited product set – the risk is still present.  • There are also analyses that believe today's price may already reflect much of the growth (“may be fairly priced”).  ⸻ Is it likely that the drop will continue today? It's never possible to say with certainty, but some considerations: • When a stock falls ~20 % in one day, it can be an “emotion-driven” move (investors locking in gains, readjusting expectations). • If no new negative news emerges, one can expect the drop to subside / stabilize – but the risk of further decline is present if: • Negative signals emerge from the pipeline or competition • The market gets the impression that management is not delivering going forward • Given that the figures were not catastrophic but a bit “disappointing” relative to expectations, today's price development will also depend on what the next quarter/year shows, and how the market interprets indications from the company. ⸻ Brief summary • Xeris delivered good growth, but some expectations were not fully met – especially profitability and certain product segments. • The market likely reacted to a “high bar” and some disappointment, even though the results are solid. • The company is optimistic and has adjusted guidance – but the risk is still open (limited product portfolio, pipeline uncertainty). • Analysts are divided – some see good growth opportunities, others believe the risk is now greater and that the stock may be highly priced. • If the drop continues today: possible, but dependent on sentiment and any new information – stabilization is as likely as further decline.
- ·6.11.First stock I ever bought. I'm 16 years old, my friend said I should… really bought 24 before it went down 20%. Getting completely traumatized here.·7.11.Just take it easy. I bought it back in '21 and a couple of months after that it was at -50%. I've held it and until yesterday it was at +165%, so give it time.
- ·6.11.Panic selling… I'm holding steady. Record quarter. I guess this is just an overreaction.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
140
Myynti
Määrä
378
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
7,75VWAP
Alin
7,5VaihtoMäärä
3,8 667 357
VWAP
Ylin
7,75Alin
7,5VaihtoMäärä
3,8 667 357
Välittäjätilasto
Dataa ei löytynyt